About this condition
Inflammatory Bowel Disease (Crohn's Disease)
Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis is characterized by chronic intestinal inflammation leading to abdominal pain, diarrhea, blood in stool, weight loss, and potential complications including strictures, fistulas, and colorectal cancer. Prevalence of Crohn's disease is approximately 1 in 1,000 in developed countries, with higher incidence in younger patients (peak onset 15–35 years). Genetic contribution is substantial: heritability is estimated at 50–80%, and the field has identified more than 200 GWAS loci associated with IBD. The first Crohn's disease susceptibility gene identified was NOD2/CARD15 in 2001, a landmark discovery that opened the field to understanding innate immune dysfunction in CD. NOD2 encodes an intracellular pattern recognition receptor that detects bacterial muramyl dipeptide (MDP), triggering NF-κB signaling and inflammatory response. Three common NOD2 variants (R702W, G908R, 1007fs) account for approximately 15–20% of population attributable risk in European ancestry CD patients.
Homozygous or compound heterozygous NOD2 variants confer approximately 20–40-fold increased Crohn's disease risk compared to non-carriers. NOD2 loss-of-function variants impair MDP sensing and reduce inflammatory responses to bacteria, paradoxically increasing disease risk through failure of appropriate bacterial containment and dysbiotic expansion of pathogenic flora. This counterintuitive mechanism—why would reduced immune response cause inflammation?—is now understood in the context of dysbiosis and barrier dysfunction. IL23R encodes interleukin-23 receptor, involved in Th17 lineage differentiation; the protective variant rs11209026 (R381Q) actually reduces Th17 polarization, suggesting IL-23/Th17 axis hyperactivation drives IBD. This discovery led directly to therapeutic development: IL-23 pathway inhibitors (ustekinumab, risankizumab, guselkumab) are now approved for CD and UC, producing dramatic clinical responses in subgroups of patients.
NOD2 genotyping provides prognostic insight into disease course: homozygous NOD2 carriers typically develop earlier-onset disease, more extensive colonic involvement, and higher rates of complications including strictures and fistulas. IL23R protective variant carriers predict better response to IL-23 inhibitors, suggesting that future pharmacogenomic prediction could guide therapy selection. Genetic understanding of IBD has principally driven drug development rather than altering individual patient management; the landmark discovery that IL23R variants were protective led directly to ustekinumab, risankizumab, and guselkumab—now approved therapies that benefit the broader IBD population. Understanding the genetic basis of IBD is shifting clinical perspective from viewing it as primarily a gastrointestinal disorder to recognizing its deep immunological underpinnings.
- Gene locus
- NOD2/CARD15 (16q12.1), IL23R (1p31.3)
